Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS-2129 tablets, which are intended for the treatment of diabetic peripheral neuropathic pain and osteoarthritis pain in adults [1] Group 1: Drug Information - Drug Name: HRS-2129 tablets [1] - Dosage Form: Tablet [1] - Clinical Trial Acceptance Numbers: CXHL2500661, CXHL2500662, CXHL2500663, CXHL2500664 [1] - Approval Conclusion: The drug meets the requirements for drug registration and is approved for clinical trials [1] Group 2: Market Context - HRS-2129 tablets are aimed at treating acute and chronic pain [1] - Currently, there are no approved drugs targeting the same mechanism in the domestic market [1] - Cumulative R&D investment for HRS-2129 tablets is approximately 112 million yuan [1]